Dietary high oleic canola oil supplemented with docosahexaenoic acid attenuates plasma proprotein convertase subtilisin kexin type 9 (PCSK9) levels in participants with cardiovascular disease risk: A randomized control trial
Pu S, Rodríguez-Pérez C, Ramprasath VR, Segura-Carretero A, Jones PJ
Vascular pharmacology · 13 citas
Etiquetas de revisión
Alimentación controladaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
- Consumo medido con
- Comida provista por los investigadores
Quién lo pagó
- Financiación
- Financiación independiente
- Universidad u hospital
- Pennsylvania State University
- Gobierno
- Agriculture and Agri-Food Canada
- Gobierno
- Manitobas Agri-Food Research and Development Initiative (ARDI)
Según 3 financiadores declarados.
Publicación
- Publicado
- 2016-07-02 · Vascul Pharmacol · vol. 87 · págs. 60–65
- Editorial
- Elsevier BV
- Citado
- 15 citas · más que el 85% de estudios similares · 1.8× el promedio de su campo
- Referencias
- 37 trabajos
- Acceso
- De pago
- Áreas de investigación
- Fatty Acid Research and Health · Lipoproteins and Cardiovascular Health · Cholesterol and Lipid Metabolism
- Palabras clave
- PCSK9, docosahexaenoic acid, dietary fat composition, LDL cholesterol, serum cholesterol, apolipoprotein(a), apolipoprotein B, cardiovascular risk, LDL receptor degradation, lipid profile
- MeSH
- humans, cardiovascular diseases, lipids, dietary fats, docosahexaenoic acids, safflower oil, oleic acid, plant oils, enzyme-linked immunosorbent assay, risk factors, cross-over studies, double-blind method, adult, middle aged, female, male, cholesterol, ldl, proprotein convertase 9, rapeseed oil
5 autores
- Shuaihua Pu🇨🇦University of Manitoba
- Celia Rodríguez‐Pérez🇪🇸Universidad de Granada; Parque Tecnológico de la Salud
- Vanu Ramkumar Ramprasath🇨🇦University of Manitoba
- Antonio Segura‐Carretero🇪🇸Universidad de Granada; Parque Tecnológico de la Salud
- Peter J.H. Jones🇨🇦 · autor de correspondenciaUniversity of Manitoba
Resumen
El texto original del estudio, en el idioma en que se publicó.
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a novel circulating protein which plays an important role in regulation of cholesterol metabolism by promoting hepatic LDL receptor degradation. However, the action of dietary fat composition on PCSK9 levels remains to be fully elucidated. The objective was to investigate the action of different dietary oils on circulating PCSK9 levels in the Canola Oil Multicenter Intervention Trial (COMIT). COMIT employed a double-blinded crossover randomized control design, consisting of five 30-d treatment periods. Diets were provided based on a 3000Kcal/d intake, including a 60g/d treatment of conventional canola oil (Canola), a high oleic canola/DHA oil blend (CanolaDHA), a corn/safflower oil blend (CornSaff), a flax/safflower oil blend (FlaxSaff) or a high oleic canola oil (CanolaOleic). Plasma PCSK9 levels were assessed using ELISA at the end of each phase. Lipid profiles (n=84) showed that CanolaDHA feeding resulted in the highest (P<0.05) serum total cholesterol (TC, 5.06±0.09mmol/L) and LDL-cholesterol levels (3.15±0.08mmol/L) across all five treatments. CanolaDHA feeding also produced the lowest (P<0.05) plasma PCSK9 concentrations (216.42±8.77ng/mL) compared to other dietary oil treatments. Plasma PCSK9 levels positively correlated (P<0.05) with serum TC, LDL-cholesterol, apolipoprotein A, and apolipoprotein B levels but did not correlate to HDL-cholesterol levels. Results indicate that post-treatment response in PCSK9 may be altered with the CanolaDHA diet. In conclusion, the elevated LDL-C levels from a DHA oil treatment may not be relevant for the observed decline in PCSK9 levels.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.